Biosimilar Breakthrough: Lupin Inks $50 Million Certolizumab Pact With Zentiva

Lupin Ltd has signed a strategic licensing and supply agreement with Czech-based Zentiva for the global commercialisation of its biosimilar Certolizumab Pegol, a treatment for autoimmune conditions such as rheumatoid arthritis and Crohn’s disease. The deal marks a major milestone in Lupin’s biosimilar expansion strategy, targeting regulated markets across Europe and North America.

Key Highlights From The Agreement

- Zentiva will make an upfront payment of USD 10 million to Lupin, with total milestone-linked payments reaching up to USD 50 million  
- Lupin will handle development, manufacturing, and supply of the biosimilar  
- Zentiva will lead commercialisation in Europe and CIS countries, leveraging its regulatory and distribution infrastructure  
- Lupin retains commercial rights in the US, Canada, and other global markets  
- Both companies will co-invest in development and share profits from defined territories  

Strategic Scope And Market Impact

- The agreement excludes Australia, Japan, Brazil, the Philippines, and India  
- The biosimilar targets a high-growth segment with multiple biologics nearing patent expiry  
- The partnership enhances Lupin’s global reach while ensuring cost-effective access to biologics  
- Zentiva’s European footprint complements Lupin’s manufacturing strength and regulatory pipeline  

Outlook

This collaboration is expected to accelerate Lupin’s biosimilar ambitions and deepen its presence in regulated markets. With Certolizumab Pegol’s global market potential and Zentiva’s commercial muscle, the alliance could set a benchmark for future biosimilar partnerships.

Sources: Financial Express, Business Standard, Economic Times Markets, Lupin Ltd regulatory filings, Reuters India Business Feed, ICICIdirect, MoneyWorks4Me, IDBI Capital Markets